Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model

• Main Authors: R. Ling (Author), B. White (Author), J. Roberts (Author), M. Cretikos (Author), M. V. Howard (Author), P. S. Haber (Author), N. Lintzeris (Author), P. Reeves (Author), A. J. Dunlop (Author), A. Searles (Author)
• Format: Book
• Published: BMC, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background In 2019 daily liquid methadone and sublingual buprenorphine-naloxone were primary opioid agonist treatments for correctional centres in New South Wales, Australia. However, both had significant potential for diversion to other patients, and their daily administration was resource...